CSL Behring – Withdrawal of Hizentra® [immune globulin subcutaneous (human)]

- On October 27, 2021, CSL Behring announced a patient-level withdrawal of one lot of Hizentra [immune globulin subcutaneous (human)] due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration.
- Other Hizentra products that are not being removed from the market are available for patients to use.
- The withdrawn lot was shipped from CSL Behring in September 2021.

Product Description	NDC	Lot # (Expiration Date)
Hizentra [immune globulin subcutaneous (human)] 20% liquid	44206-0455-10	P100340460 (11/12/2023)

- Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
- Injection-site reactions and hypersensitivity are a known risk with subcutaneous immune globulin products.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the withdrawn Hizentra.
- Contact CSL Behring Medical Information by phone at **1-800-504-5434** or by email at **MedinfoNA@cslbehring.com** for more information about the withdrawal.